Regulus Therapeutics (RGLS) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Regulus Therapeutics (RGLS) PT Raised to $1.37 at BMO Capital, Sees Shares 'Range-Bound'
March 8, 2018 5:52 AM ESTBMO Capital raised its price target on Regulus Therapeutics (NASDAQ: RGLS) to $1.37 (from $1.00) while maintaining a Market Perform rating.
"We believe investor focus will remain on the continued progress of Regulus's pipeline, particularly RG-012 for Alport syndrome where slower-than-expected enrollment and site... More
